Nebivolol
- Chemical Name: Nebivolol
- CAS No.: 99200-09-6
- MF: C22H25F2NO4
- MW: 405.43
- Purity:≥98% or according to customer requested
- Product Categories:Pharmaceutical raw materials;APIs;Circulatory system drugs;β- adrenergic receptor blockers
- Test method: HPLC
Description
What is Nebivolol?
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007.
It is also a beta-blocker and antihypertensive medication that has additional vasodilatory activity mediated by nitric oxide release. Nebivolol has yet to be linked to instances of clinically apparent liver injury.
Product Name: | Nebivolol |
Synonyms: | Nebivololum |
CAS: | 99200-09-6 |
MF: | C22H25F2NO4 |
MW: | 405.43 |
Product Categories: | Pharmaceutical raw materials;APIs;Circulatory system drugs;β- adrenergic receptor blockers |
Boiling point | 600.5±55.0 °C(Predicted) |
density | 1.309±0.06 g/cm3(Predicted) |
storage temp. | Keep in dark place,Sealed in dry,2-8°C |
pka | 14.29±0.20(Predicted) |
Nebivolol, also known as Leibvurol, is a highly selective fat-soluble β1 receptor blocker. It was successfully developed by American Family Products. It is an antihypertensive drug that blocks adrenergic β1 receptors. The intensity of action is 290 times that of blocking adrenergic β2 receptors, which is more specific than the currently known selective β1 receptor blockers atenolol, metoprolol, bisoprolol, etc.
Nebivolol powder does not cause bronchial smooth muscle and vascular smooth muscle contraction, has no endogenous sympathomimetic activity, no membrane stabilization, and does not bind to serotonin receptors, dopamine receptors, adrenergic α1 and α2 receptors.
Nebivolol is divided into left-handed body and right-handed body. In vitro studies have shown that the β-receptor blocking effect of nebivolol is mainly derived from the right-handed body, but other effects depend on the coexistence of the left-handed body and the right-handed body. The racemate is clinically used, and the ratio of the two is roughly the same.
Technical Support & Resources
Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
MSDS: MSDS available.
COA: COA can be available if you send us inquiry.
Email us at: info@maxmedchem.com for more details.